Fundamental evaluation of apolipoprotein B-48 by chemiluminescence enzyme immunoassay--identification of apolipoprotein B-48 with immunoblotting

• Published in: Rinsho byori. The Japanese journal of clinical pathology Vol. 55; no. 6; p. 528
• Main Authors: Sato, Itsuko, Fujioka, Yoshio, Hayashi, Fujio, Mukai, Masahiko, Kawano, Seiji, Ishikawa, Yuichi, Yamashita, Shizuya, Kumagai, Shunichi
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.06.2007
• Subjects: Apolipoprotein B-48 - blood; Apolipoprotein B-48 - isolation & purification; Atherosclerosis - etiology; Biomarkers - blood; Humans; Immunoblotting; Immunoenzyme Techniques - methods; Lipoproteins - metabolism; Risk Factors
• ISSN: 0047-1860

Apolipoprotein B-48 (apo B-48) is a constituent of chylomicrons and chylomicron remnants, and its fasting concentration has been reported to be a marker of postprandial hyperlipidemia, which is thought to be a risk factor of atherosclerosis. We evaluated the serum apo B-48 concentrations by chemiluminescence enzyme immunoassay (CLEIA), which was recently introduced as Lumipulse f fully automated immunosaasy analyzer by Fujirebio Inc (Tokyo, Japan), and performed immunoblotting on agarose gel electrophoresis with anti-apo B-48 antibody. Apo B-48 assay was intra-assay reproducible (CVs: 1.9-3.1%) and inter-assay reproducible (CVs: 2.2-4.4%). The assay range for apo B-48 was from 0.2 to 40.0 microg/ml. The effects of interfering substances such as free/conjugated birirubin, hemoglobin, Intrafat, ascorbic acid and rheumatoid factor were negligible. For storage, it was preferable to freeze, and to avoid frozen-thaw process as much as possible. Anti-apo B-48 antibody was reactive over a wide range from origin to the position of very-low-density lipoproteins in immunoblotting after agarose gel electrophoresis. Apo B-48 measurement by CLEIA was feasible to clinical use for the assessment of lipoprotein metabolism.